196 related articles for article (PubMed ID: 36958766)
1. Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension.
Eder L; Gladman DD; Mease P; Pollock RA; Luna R; Aydin SZ; Ogdie A; Polachek A; Gruben D; Cadatal MJ; Kinch C; Strand V
RMD Open; 2023 Mar; 9(1):. PubMed ID: 36958766
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials.
Kivitz AJ; FitzGerald O; Nash P; Pang S; Azevedo VF; Wang C; Takiya L
Clin Rheumatol; 2022 Feb; 41(2):499-511. PubMed ID: 34510295
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of tofacitinib for chronic plaque psoriasis and psoriatic arthritis: a systematic review and meta-analysis of randomized controlled trials.
Dai Q; Zhang Y; Liu Q; Zhang C
Clin Rheumatol; 2024 May; 43(5):1605-1613. PubMed ID: 38517652
[TBL] [Abstract][Full Text] [Related]
4. Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis.
Giles JT; Ogdie A; Gomez Reino JJ; Helliwell P; Germino R; Stockert L; Young P; Joseph W; Mundayat R; Graham D; Ritchlin C
RMD Open; 2021 Jan; 7(1):. PubMed ID: 33452181
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies.
Mease PJ; Orbai AM; FitzGerald O; Bedaiwi M; Dona L Fleishaker ; Mundayat R; Young P; Helliwell PS
Arthritis Res Ther; 2023 Aug; 25(1):153. PubMed ID: 37608391
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study.
Leng X; Lin W; Liu S; Kanik K; Wang C; Wan W; Jiang Z; Liu Y; Liu S; Zhang Z; Zhang Z; Xu J; Tan W; Hu J; Li J; Liu J; Gunay LM; Dina O; Kinch C; Zeng X
RMD Open; 2023 Jan; 9(1):. PubMed ID: 36720560
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies.
Nash P; Coates LC; Fleischmann R; Papp KA; Gomez-Reino JJ; Kanik KS; Wang C; Wu J; Menon S; Hendrikx T; Ports WC
Rheumatol Ther; 2018 Dec; 5(2):567-582. PubMed ID: 30414064
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
Mease P; Hall S; FitzGerald O; van der Heijde D; Merola JF; Avila-Zapata F; Cieślak D; Graham D; Wang C; Menon S; Hendrikx T; Kanik KS
N Engl J Med; 2017 Oct; 377(16):1537-1550. PubMed ID: 29045212
[TBL] [Abstract][Full Text] [Related]
9. Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo.
Gladman DD; Coates LC; Wu J; Fallon L; Bacci ED; Cappelleri JC; Bushmakin AG; Helliwell PS
Arthritis Res Ther; 2022 Feb; 24(1):40. PubMed ID: 35139908
[TBL] [Abstract][Full Text] [Related]
10. Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies.
Ritchlin CT; Giles JT; Ogdie A; Gomez-Reino JJ; Helliwell P; Young P; Wang C; Wu J; Romero AB; Woolcott J; Stockert L
ACR Open Rheumatol; 2020 Oct; 2(10):543-554. PubMed ID: 32910531
[TBL] [Abstract][Full Text] [Related]
11. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.
Strand V; de Vlam K; Covarrubias-Cobos JA; Mease PJ; Gladman DD; Graham D; Wang C; Cappelleri JC; Hendrikx T; Hsu MA
RMD Open; 2019; 5(1):e000806. PubMed ID: 30713721
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.
Ritchlin C; Rahman P; Kavanaugh A; McInnes IB; Puig L; Li S; Wang Y; Shen YK; Doyle MK; Mendelsohn AM; Gottlieb AB;
Ann Rheum Dis; 2014 Jun; 73(6):990-9. PubMed ID: 24482301
[TBL] [Abstract][Full Text] [Related]
13. Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies.
Orbai AM; Mease PJ; Helliwell PS; FitzGerald O; Fleishaker DL; Mundayat R; Young P
BMC Rheumatol; 2022 Sep; 6(1):68. PubMed ID: 36045453
[TBL] [Abstract][Full Text] [Related]
14. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.
Helliwell P; Coates LC; FitzGerald O; Nash P; Soriano ER; Elaine Husni M; Hsu MA; Kanik KS; Hendrikx T; Wu J; Kudlacz E
Arthritis Res Ther; 2018 Oct; 20(1):242. PubMed ID: 30373651
[TBL] [Abstract][Full Text] [Related]
15. The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis.
Dougados M; Taylor PC; Bingham CO; Fallon L; Brault Y; Roychoudhury S; Wang L; Kessouri M
RMD Open; 2022 Sep; 8(2):. PubMed ID: 36814062
[TBL] [Abstract][Full Text] [Related]
16. Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies.
Schneeberger EE; Citera G; Nash P; Smolen JS; Mease PJ; Soriano ER; Helling C; Szumski AE; Mundayat R; de León DP
Semin Arthritis Rheum; 2023 Feb; 58():152134. PubMed ID: 36476498
[TBL] [Abstract][Full Text] [Related]
17. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R
Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
[TBL] [Abstract][Full Text] [Related]
18. Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies.
Merola JF; Papp KA; Nash P; Gratacós J; Boehncke WH; Thaçi D; Graham D; Hsu MA; Wang C; Wu J; Young P
J Eur Acad Dermatol Venereol; 2020 Dec; 34(12):2809-2820. PubMed ID: 32271970
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study.
Nash P; Coates LC; Kivitz AJ; Mease PJ; Gladman DD; Covarrubias-Cobos JA; FitzGerald O; Fleishaker D; Wang C; Wu J; Hsu MA; Menon S; Fallon L; Romero AB; Kanik KS
Rheumatol Ther; 2020 Sep; 7(3):553-580. PubMed ID: 32506317
[TBL] [Abstract][Full Text] [Related]
20. Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis.
Gladman DD; Orbai AM; Gomez-Reino J; Chang-Douglass S; Leoncini E; Burton HE; Kanik KS; Romero AB; Cappelleri JC; Hsu MA
Curr Ther Res Clin Exp; 2020; 93():100601. PubMed ID: 32983284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]